Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Issued (2020 - 2025)

Mirum Pharmaceuticals has reported Shares Issued over the past 6 years, most recently at -$31.1 million for Q4 2025.

  • Quarterly results put Shares Issued at -$31.1 million for Q4 2025, down 151.99% from a year ago — trailing twelve months through Sep 2025 was $18.8 million (up 28.87% YoY), and the annual figure for FY2023 was $10.5 million, down 87.84%.
  • Shares Issued for Q4 2025 was -$31.1 million at Mirum Pharmaceuticals, down from $16.1 million in the prior quarter.
  • Over the last five years, Shares Issued for MIRM hit a ceiling of $80.8 million in Q4 2022 and a floor of -$31.1 million in Q4 2025.
  • Median Shares Issued over the past 5 years was $3.0 million (2023), compared with a mean of $6.6 million.
  • Biggest five-year swings in Shares Issued: soared 4975.0% in 2022 and later plummeted 657.47% in 2024.
  • Mirum Pharmaceuticals' Shares Issued stood at $5.6 million in 2021, then soared by 1355.29% to $80.8 million in 2022, then plummeted by 97.26% to $2.2 million in 2023, then plummeted by 657.47% to -$12.4 million in 2024, then plummeted by 151.99% to -$31.1 million in 2025.
  • The last three reported values for Shares Issued were -$31.1 million (Q4 2025), $16.1 million (Q3 2025), and $8.7 million (Q2 2025) per Business Quant data.